# Resistance Rates of Mycobacterium tuberculosis Complex Strains: A Retrospective Study in Türkiye

**Authors:** Melda Payaslıoğlu, İmran Sağlık, Cüneyt Özakın

PMC · DOI: 10.3390/medicina61061060 · Medicina · 2025-06-09

## TL;DR

This study analyzed drug resistance in tuberculosis strains in Türkiye from 1996 to 2023, finding that nearly 20% were resistant to at least one first-line drug.

## Contribution

The study provides updated resistance rates of M. tuberculosis in western Türkiye over a 27-year period.

## Key findings

- 19.2% of M. tuberculosis isolates were resistant to at least one first-line drug.
- 2.9% of isolates were multidrug-resistant, showing resistance to two or more first-line drugs.

## Abstract

Background and Objectives: Tuberculosis (TB) is one of the most common infectious diseases in developing countries. The resistance of the causative agent, Mycobacterium tuberculosis, to two or more first-line anti-TB drugs results in multidrug-resistant (MDR) TB, posing a serious challenge to the control of TB worldwide. This study was designed to determine the changes in drug resistance over time in TB strains isolated from patients in all departments of Uludağ University Hospital in western Türkiye. Materials and Methods: We retrospectively analyzed 104,598 clinical samples sent to our laboratory for the investigation of the presence of TB between 1996 and 2023. BACTEC 460 TB, BACTEC MGIT 960 culture systems and Löwenstein–Jensen medium were used for the culture of these samples. The susceptibility of M. tuberculosis complex strains grown in culture to isoniazid (INH) (0.1 μg/mL), rifampicin (RIF) (1.0 μg/mL), ethambutol (ETB) (5.0 μg/mL) and streptomycin (SM) (1.0 μg/mL) antibiotics was studied according to the manufacturer’s recommendation. Results: Out of 104,598 patient samples, 2752 (2.6%) were culture-positive, and the susceptibility test results of 1869 of these were analyzed. Of the isolates, 358 (19.2%) were found to be resistant to at least one first-line drug, i.e., INH, RIF, ETB, or SM. In addition, 2.9% were resistant to two or more first-line drugs. Conclusions: Drug susceptibility testing is essential to ensure the optimal treatment and control of drug-resistant TB strains. This study highlights the value of ongoing efforts to control tuberculosis drug resistance in the fight against this disease.

## Linked entities

- **Chemicals:** isoniazid (PubChem CID 3767), rifampicin (PubChem CID 135398735), ethambutol (PubChem CID 14052), streptomycin (PubChem CID 5297)
- **Diseases:** tuberculosis (MONDO:0018076)
- **Species:** Mycobacterium tuberculosis (taxon 1773)

## Full-text entities

- **Diseases:** multidrug-resistant (MDR) TB (MESH:D018088), TB (MESH:D014376), infectious diseases (MESH:D003141)
- **Chemicals:** INH (MESH:D007538), SM (MESH:D013307), RIF (MESH:D012293), ETB (MESH:D004977), Lowenstein-Jensen medium (-)
- **Species:** Mycobacterium tuberculosis (species) [taxon 1773], Mycobacterium tuberculosis complex (species group) [taxon 77643], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12195593/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12195593/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12195593/full.md

---
Source: https://tomesphere.com/paper/PMC12195593